HK Stock Market Move | CANBRIDGE-B(01228) rose by nearly 18% during trading. Its three rare disease products have all been included in the 2026 Beijing Universal Health Insurance Program.

CANBRIDGE-B (01228) rose nearly 18% during trading, and at the time of writing, it was up 11.76% to HK$2.09 with a turnover of HK$10.2188 million. On the news front, the details of the 2026 "Beijing Inclusive Health Insurance" have been recently announced, with three rare disease products from Beihai Kangcheng included, among which Gofenning made its first appearance in "Inclusive Health Insurance." It is reported that Gofenning was approved for listing on May 13th of this year. On July 2nd, Gofenning was prescribed for the first time at Xinhua Hospital affiliated with Shanghai Jiao Tong University School of Medicine, marking the official entry of the drug into clinical applications and significantly improving accessibility to medication for domestic patients in the future.